HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for BioNTech (NASDAQ:BNTX) and maintained a price target of $113, as stated by analyst Robert Burns.
September 16, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for BioNTech and maintained a price target of $113, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $113 price target by HC Wainwright & Co. suggests positive sentiment and confidence in BioNTech's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100